Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVS NASDAQ:CTOR NASDAQ:EXOZ NASDAQ:GELS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.79+0.3%$1.99$1.54▼$5.50$61.85M1.27831,315 shs691,259 shsCTORCitius Oncology$0.69+4.4%$0.82$0.49▼$6.19$64.44M3.42203,210 shs24,188 shsEXOZeXoZymes$7.47+5.1%$9.83$7.08▼$18.40$63.30M2.664,468 shs1,229 shsGELSGelteq$1.12+12.6%$0.59$0.39▼$2.12$11.94M-0.192.52 million shs59.83 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio0.00%-4.24%-12.97%-36.11%-35.88%CTORCitius Oncology0.00%-14.87%-31.07%-17.61%-54.83%EXOZeXoZymes0.00%-21.94%-27.32%-2.67%-44.57%GELSGelteq0.00%+99.20%+127.17%+23.75%-52.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.79+0.3%$1.99$1.54▼$5.50$61.85M1.27831,315 shs691,259 shsCTORCitius Oncology$0.69+4.4%$0.82$0.49▼$6.19$64.44M3.42203,210 shs24,188 shsEXOZeXoZymes$7.47+5.1%$9.83$7.08▼$18.40$63.30M2.664,468 shs1,229 shsGELSGelteq$1.12+12.6%$0.59$0.39▼$2.12$11.94M-0.192.52 million shs59.83 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio0.00%-4.24%-12.97%-36.11%-35.88%CTORCitius Oncology0.00%-14.87%-31.07%-17.61%-54.83%EXOZeXoZymes0.00%-21.94%-27.32%-2.67%-44.57%GELSGelteq0.00%+99.20%+127.17%+23.75%-52.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 2.25Hold$13.50656.30% UpsideCTORCitius Oncology 2.33Hold$6.00765.80% UpsideEXOZeXoZymes 1.00SellN/AN/AGELSGelteq 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest GELS, EXOZ, CTOR, and ANVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026EXOZeXoZymes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/7/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/29/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/14/2026ANVSAnnovis Bio Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.64 per shareN/ACTORCitius OncologyN/AN/AN/AN/A$0.54 per shareN/AEXOZeXoZymes$70K904.33N/AN/A$0.40 per share18.66GELSGelteq$110K108.56N/AN/A$1.08 per share1.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$28.85M-$1.71N/AN/AN/AN/A-318.08%-215.47%8/18/2026 (Estimated)CTORCitius Oncology-$24.76M-$0.47N/AN/AN/AN/A-99.47%-42.16%8/18/2026 (Estimated)EXOZeXoZymes-$9.16M-$1.14N/AN/AN/AN/A-220.63%-141.26%N/AGELSGelteq-$4.30MN/AN/AN/AN/AN/AN/AN/AN/ALatest GELS, EXOZ, CTOR, and ANVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ANVSAnnovis Bio-$0.3950-$0.63-$0.2350-$0.63N/AN/A5/15/2026Q2 2026CTORCitius Oncology-$0.01-$0.27-$0.26-$0.27$7.00 million$1.67 million5/14/2026Q1 2026EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/A3/30/2026Q4 2025EXOZeXoZymesN/A-$0.31N/A-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A1.271.27CTORCitius Oncology0.110.500.12EXOZeXoZymes0.031.321.32GELSGelteqN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%CTORCitius Oncology70.52%EXOZeXoZymesN/AGELSGelteqN/AInsider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%CTORCitius Oncology9.80%EXOZeXoZymes72.41%GELSGelteqN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio334.65 million27.44 millionOptionableCTORCitius OncologyN/A92.98 million83.87 millionN/AEXOZeXoZymes298.48 million2.34 millionN/AGELSGelteqN/A10.71 millionN/AN/AGELS, EXOZ, CTOR, and ANVS HeadlinesRecent News About These CompaniesGelteq Limited (NASDAQ:GELS) Sees Significant Decline in Short InterestJune 15 at 2:14 AM | americanbankingnews.comGelteq Limited: Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq Technology for Animal Health ApplicationsJune 13 at 10:14 AM | finanznachrichten.deGelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating ...June 12 at 11:47 PM | caledonianrecord.comCWhat's going on with Gelteq stock Friday?June 12 at 11:47 PM | msn.comGelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health ApplicationsJune 12 at 12:30 PM | globenewswire.comGelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial ExpansionJune 4, 2026 | globenewswire.comGelteq Calls June 19 Special Meeting to Approve Potentially Dilutive Convertible Note Share IssuanceJune 2, 2026 | tipranks.comGelteq Limited: Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory PathwayMay 20, 2026 | finanznachrichten.deGelteq startet klinische Studie für antiparasitäres TierarzneimittelMay 20, 2026 | de.investing.comGelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory PathwayMay 20, 2026 | globenewswire.comHealthy Extracts Q1 2026 Net Revenue Up 73% to Record $1.6 Million, Driving Positive EBITDAMay 14, 2026 | accessnewswire.comAGelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue GrowthMay 12, 2026 | globenewswire.comGelteq LimitedApril 15, 2026 | edition.cnn.comGelteq Limited Ordinary Shares (GELS) Real-TimeApril 10, 2026 | nasdaq.comHealthy Extracts Reports 2025 Net Revenue Up 45% to Record $4.5 MillionApril 8, 2026 | accessnewswire.comAHealthy Extracts Reports Preliminary 2025 Results, Net Revenue Expected Up 45% to Record $4.5 MillionApril 2, 2026 | accessnewswire.comAGelteq Warned by Nasdaq Over Minimum Bid Price ComplianceMarch 24, 2026 | tipranks.comGelteq Limited and Healthy Extracts Inc. Sign Strategic Partnership to Launch Gel-Based Nutraceutical ProductsFebruary 11, 2026 | quiverquant.comQGelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial PartnershipFebruary 11, 2026 | globenewswire.comGelteq announces preclinical results on medicinal cannabinoid absorptionJanuary 14, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAfter NVIDIA, Broadcom's Earnings Are Next—Here's What to WatchBy Leo Miller | May 26, 2026Rocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?By Ryan Hasson | June 4, 20263 Stocks Rallying on Micron's Price Boost: Substance or Hype?By Dan Schmidt | May 28, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 20263 Stocks With Fresh Catalysts to Watch Before July 4By Chris Markoch | June 8, 2026GELS, EXOZ, CTOR, and ANVS Company DescriptionsAnnovis Bio NYSE:ANVS$1.78 +0.01 (+0.28%) Closing price 03:59 PM EasternExtended Trading$1.79 +0.00 (+0.17%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Citius Oncology NASDAQ:CTOR$0.68 +0.02 (+2.44%) Closing price 04:00 PM EasternExtended Trading$0.69 +0.01 (+2.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.eXoZymes NASDAQ:EXOZ$7.35 +0.25 (+3.52%) Closing price 04:00 PM EasternExtended Trading$7.44 +0.10 (+1.29%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Gelteq NASDAQ:GELS$1.16 +0.17 (+17.17%) Closing price 04:00 PM EasternExtended Trading$1.19 +0.03 (+2.33%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
